FTC (Federal Trade Commission) probes DaVita/Gambro Healthcare deal further
This article was originally published in Clinica
Executive Summary
The US Federal Trade Commission (FTC) has requested additional information from DaVita and Gambro regarding the former's planned $3.05bn acquisition of the latter's Gambro Healthcare US dialysis services business. A spokesperson for Stockholm, Sweden-based Gambro told Clinica: "We believe that any antitrust issues can be overcome." She added that the deal was a very good one for both parties.